3Z Pharmaceuticals employs innovative technologies in drug discovery, particularly focusing on central nervous system (CNS) disorders. The company utilizes a unique zebrafish screening platform, which allows for high-throughput in vivo screening of both novel and repurposed small molecule drugs. This method is particularly advantageous for drug repurposing, as it leverages existing licensed drugs for new medical indications, thereby accelerating the drug development process. The zebrafish model is not only cost-effective but also facilitates the identification of therapeutics that are non-stimulant and have fewer side effects, addressing significant gaps in the treatment of conditions like ADHD and insomnia.

In addition to its zebrafish platform, 3Z Pharmaceuticals has formed a strategic partnership with biotx.ai to enhance its drug development capabilities through advanced AI modeling techniques. This collaboration aims to bridge the gap between animal studies and human clinical trials, improving the translation of therapeutic findings. By employing AI-powered human genetics-based modeling, the partnership seeks to predict the effects of lead therapeutic targets on ADHD and assess their potential impact on other disorders. This approach is expected to de-risk the drug development process, providing valuable insights that could significantly enhance the efficiency and success rate of clinical trials.

Iceland

3Z uses advanced disease modeling and behavioral genetics to discover novel drug candidates for CNS disorders.

3Z Pharmaceuticals

Company Details